Clinical trials
Real World Data clinical trials
Below are recruiting real world data clinical trials, each written for real people, not researchers. We’re tracking 122 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07127978Recruiting
Study of Givinostat in people with Duchenne muscular dystrophy
This study is for people with Duchenne muscular dystrophy (DMD) who are taking Givinostat, a daily oral medicine. Researchers will look at real-world data to see how the medicine works in everyday life, including lab results and how it's being used.
Little Rock, ArkansasAges 6 years+ - NCT07117136Recruiting
Blinatumomab after standard treatment for B-ALL
This trial is studying how well the drug blinatumomab works for adults with B-cell acute lymphoblastic leukemia (B-ALL) when it is given after the first phase of treatment. It looks at patient data to understand real-world outcomes.
Jacksonville, FloridaAges 18 years+ - NCT07109375Recruiting
Long-term study of pegunigalsidase alfa for Fabry disease
This study observes how well the medication pegunigalsidase alfa works over a long period in people with Fabry disease. It helps doctors learn more about managing the condition in everyday life.
ArezzoAges 18 years+ - NCT07102368Recruiting
Study of guselkumab for inflammatory bowel disease in Germany
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
BerlinAges 18 years+ - NCT07091019Recruiting
CML patient experience study on standard TKI therapy
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Birmingham, AlabamaAges 18–100 - NCT07073755Recruiting
Study of next treatments after targeted therapy resistance for advanced breast cancer
This study looks at what happens when people with advanced breast cancer switch to a new treatment after their cancer becomes resistant to targeted therapies like CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd. Researchers want to understand which next treatments work best in real life.
Changsha, HunanAges 18 years+ - NCT06799338Recruiting
Study of lenacapavir for HIV treatment in France
This study looks at how well lenacapavir works when added to a personalized HIV treatment plan. If you have HIV and received lenacapavir as your first dose between June 2023 and June 2024, this research may help understand its real-world effects.
Paris, Île-de-France RegionAges 18 years+ - NCT07055607Enrolling by invitation
Real-world study of Wegovy for weight management
This study observes how Wegovy works in everyday medical practice for people who are starting it for the first time. It will help doctors learn more about its real-life benefits and safety.
BarcelonaAges 18 years+ - NCT07052396Recruiting
Dupilumab for COPD: long-term real-world study
This study looks at how well dupilumab works over time for people with COPD who still have symptoms despite standard treatments and who have a certain type of inflammation (elevated eosinophils). It uses data from regular doctor visits and patient questionnaires to understand real-world benefits and safety.
AuerbachAges 18 years+ - NCT07039604Recruiting
Real-world study of PADN for pulmonary artery hypertension
This study tracks how well a procedure called PADN works for people with pulmonary artery hypertension (PAH) in real-life medical settings. PADN is a minimally invasive treatment that targets nerves around the lungs to help lower blood pressure in the arteries.
Nanjing, JiangsuAges Any age - NCT06899204Recruiting
Abrocitinib for atopic dermatitis after biologic therapy
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
San Diego, CaliforniaAges 12 years+ - NCT06846996Recruiting
Study of trastuzumab deruxtecan for advanced stomach cancer
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
BeijingAges 18 years+ - NCT02280733Recruiting
Chronic wound registry for real-world care documentation
This study is a real-world registry that collects information about chronic wounds and ulcers as they’re treated in everyday settings. It may help improve how care is tracked and supported, even if you don’t get a new medicine from the study.
The Woodlands, TexasAges Any age - NCT06808685Recruiting
Study of Elovie for advanced colorectal cancer
This study looks at how well a biosimilar version of bevacizumab (Elovie) works in people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if Elovie is safe and effective when used as the first treatment for this cancer.
Vitória, Espírito SantoAges 18 years+ - NCT06725030Recruiting
Robotic surgery for lymphedema (Symani System)
This trial uses a robotic arm called Symani to help surgeons perform more precise microsurgery (working on tiny blood vessels and lymph channels). It is for adults with moderate lymphedema in one arm or leg who have already tried standard lymphedema therapy and still have swelling.
Beverly Hills, CaliforniaAges 22 years+ - NCT06727227Recruiting
Study of Enhertu for HER2-low breast cancer
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
Panagyurishte, PazardzhikAges 18 years+ - NCT06716801Recruiting
How cenobamate works as early add-on treatment for epilepsy
This study looks at how well cenobamate works when added to other seizure medications for adults with focal epilepsy. It uses real-world data from medical records to see how people respond to treatment.
Paris, FranceAges 18 years+ - NCT06483698Recruiting
Tracking recovery after early lung cancer surgery
This study follows people with stage I lung cancer to see how they do after surgery. It aims to learn what affects recovery and long-term outcomes.
Beijing, Beijing MunicipalityAges 18–85 - NCT06566170Recruiting
Donanemab for early Alzheimer's: a real-world study
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Huntsville, AlabamaAges 60 years+ - NCT06517719Recruiting
Real-world study of Pluvicto for advanced prostate cancer
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
Konstanz, Baden-WurttembergAges 18–99 - NCT06487078Recruiting
Study of Lorlatinib for untreated ALK-positive lung cancer
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Paris, ParisAges 18 years+ - NCT06306573Enrolling by invitation
CardioMEMS heart pressure monitor study in Medicare patients
This study looks at how well the CardioMEMS heart pressure monitor works for people with heart failure who are on Medicare. It gathers real-world information to see if the sensor helps improve health outcomes.
Atlanta, GeorgiaAges 18 years+ - NCT06192576Recruiting
Long-term safety study of olipudase alfa in children under 2 with ASMD
This study looks at the long-term safety and effects of olipudase alfa in children under 2 years old with acid sphingomyelinase deficiency (ASMD), a rare genetic condition. It aims to see how the treatment works over time and if it is safe for young children.
Chicago, IllinoisAges Up to 2 years - NCT06144229Enrolling by invitation
HPV Vaccine in Women with HIV
This study looks at how well the HPV vaccine works in women living with HIV and whether it helps make cervical cancer screening more accurate. If you are a woman with HIV between 21 and 40 years old and already part of certain other HIV studies, you may be able to join.
Denver, ColoradoAges 21–40
Hear when a new Real World Data trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for real world data?
- Yes. Clin2 currently lists 122 recruiting real world data studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a real world data trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a real world data trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.